Tuesday, 17 December 2019

Heart Tumor Market 2019–By Identifying the Key Market Segments and Key players holding market share

Heart Tumor Market Scenario
According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.
The Global Heart Tumor Market is expected to grow at a CAGR of approximately 7.1% during the forecast period.
Cardiac tumors is a rare disease that aredifficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors  is attributed to various types of  cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on  the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.
A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.
Heart Tumor Market Key Players
Some of key the players in the Global heart tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Heart Tumor Market Segmentation
The heart tumor is segmented on the basis of type, diagnosis, treatment.
On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.
On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.
On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery 
International Heart Tumor Market Regional Analysis
The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.
The growing demand for outpatient surgeries and increasing preference of specialized cardiac imaging devices are some of the major factors intended to cost-effective technology, which further drives the demand for heart tumor treatment in the European region.
Increasing prevalence of metastatic tumors, which require surgical procedures and growing medical tourism in Asia Pacific region are favoring the growth of this market. According to the WHO estimate, 75% of the cardiovascular diseases occur are in low and middle income regions including Asia Pacific and the Middle East and Africa regions.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Spongiform Encephalopathy Market Value Share, Supply Demand, share and Value Chain 2019

Market Scenario
Transmissible spongiform encephalopathy (TSEs) or prion diseases are a group of invariably fatal conditions that affect central nervous system (CNS) and more specifically the brain and spinal cord. The most commonly known prion diseases in human are Fatal Familial Insomnia, Creutzfeldt - Jakob disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru, and most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.
BSE (bovine spongiform encephalopathy) is one of the most common neurological disorder found in cattle that results from a transmissible agent called a prion. According to the Centers for Disease Control and Prevention, five cases of BSE are found in the U.S. and 20 in Canada in 2017.
A number of factors such as rising facilities for patients affected by encephalopathy, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of the global spongiform encephalopathy market.
Despite these drivers, challenges in research and development, and poor healthcare system in low and middle-income countries may hamper the growth of the market.
It is estimated that spongiform encephalopathy market is expected to grow at a healthy CAGR of 6.1% during the forecast period 2017-2023.
Key Players
Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.
Regional Analysis
The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.
Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region
The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
The Middle East & Africa owns the least share of the global spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.
Segmentation
The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.
On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).
On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.
On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/spongiform-encephalopathy-market-5031
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Next Generation Sequencing Market 2019 Growing Trend and Demand in Healthcare Sector 2023

Market Research Future (MRFR) speculates that the global next generation sequencing market is presumed to demonstrate a healthy growth rate during the forecast period (2018-2023) owing to the technological advancements. Next-generation sequencing (NGS), also termed as high throughput sequencing technology or massively parallel sequencing, has revolutionized the biological sciences. The NGS technology has transformed genomic research to an advanced level and allows to sequence a complete human genome in a small duration. The genetic material is pulled out in this process, fragmented, and associated with primers and adapters for amplification.
Competitive Dashboard
The prominent players operating the global Next Generation Sequencing (NGS) Market Size Share and Growth Analysis by Thermo Fisher Scientific Inc. (US), Macrogen Inc. (South Korea), BGI (China), Oxford Nanopore Technologies Ltd. (UK), PerkinElmer (US), QIAGEN N. V. (Germany), Agilent Technologies (US), Illumina Inc. (US), Eurofins Scientific (Luxembourg), and Pacific Biosciences of California Inc. (US).
Market Potential and Pitfalls
With the emergence of high throughput screening technology, there have been substantial changes in the sequencing process by reduced sequencing cost and offering speed. The technology is propelling at a rapid pace owing to its application in clinical, agricultural, and forensic areas. For instance, NGS helps to detect various clinical applications such as cancer and its infectious disease and several genetic disorders. The augmenting awareness regarding next-generation sequencing, technological advancements, rising acquisitions and mergers among the global players, and growth in genome mapping programs are considered some of the major factors promoting the market growth throughout the appraisal period. NGS allows the researchers to study biological systems and perform a range of applications at a level never before possible with the help of scalability, ultra-high throughput, and speed. Pacific Biosciences of California, Illumina, Oxford Nanopore technology and Thermo Fisher scientific provides NGS instruments based on technologies like sequencing by ligation, reversible terminator sequencing, single-molecule, ion semiconductor sequencing technology, real-time sequencing (SMRT), and nanopore sequencing technology. The constant technological advancements and a wide range of diagnostic applications are making user-friendly and more efficient. Such factors are further bolstering the market growth across the globe.
Global Next Generation Sequencing Market: Segmental Analysis
The global next generation sequencing market has been segmented on the basis of service and product, technology, end-user, and application.
By mode of technology, the global next-generation sequencing market has been segmented into whole exome sequencing, whole genome sequencing, methyl sequencing, CHIP sequencing, RNA sequencing, targeted resequencing, and de novo sequencing.
By mode of service and product, the global next-generation sequencing market has been segmented into consumables, sample preparation, sequencing services, and platforms and services for platforms. Among these, the consumables segment is likely to occupy the largest market share owing to the increasing sequencing procedures, advancements in the sequencing technologies, rising adoption and installation of NGS platforms, and launch of easy to use consumables.
By mode of application, the global next-generation sequencing market has been segmented into the genetic screening, drug discovery, agriculture and animal research, diagnostics, and others. Among these, the diagnostic segment is predicted to experience the highest growth rate owing to the rising number of new cancer cases globally, growing focus of key market players, and favorable reimbursement policies for NGS-based tests.
By mode of end-users, the global next-generation sequencing market has been segmented into hospitals and clinics, academic institutes and research centers, pharmaceutical and biotechnology companies, and others.
Browse More Information @ https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354 
Regional Insights
Geographically, the next generation sequencing market spans across regions namely, Europe, North America, Asia Pacific, and the Middle East & Africa.
Among all the regions, the North American region is predicted to occupy the largest market share and is anticipated to retain its dominance in the coming years. The growth is credited to the rising consumer requirements and growing competition among the market players through mergers and acquisitions. Moreover, the increasing number of funds coupled with the initiatives adopted by the government in order to reduce the cases of cancer are some of the other factors likely to trigger the market growth across the globe.
The European region is anticipated to occupy the second largest share in the global market. The growth is credited to the presence of pioneer NGS technology, and a refined population interested in NGS technology. On the other hand, diverse mandates coupled with a fragmented market across Europe is presumed to limit the market growth in this region.
The Asia Pacific region is considered to register significant growth in the coming years owing to the access to optimal treatment facilities coupled with the rising demand for advanced technology, increasing disposable income, better adoption rate, and growing investments by the pharmaceutical companies.

Monday, 16 December 2019

Superdisintegrants Market Expected to Boost during 2019 To 2023

Market Scenario:
The Global Superdisintegrants Market is anticipted to grow at an optimistic CAGR of 7.9% during the forecast period from 2018 to 2023. Disintegrants are substances which are included in drug formula to allow proper disintegration of the capsule or tablet into easily dissolvable particles. This plays a vital function in the fast absorption of medicine which increases its efficacy. Superdisintegrants are slightly modified disintegrants which offer higher efficiency than their traditional counterparts. Observed to have valued at USD 371 Mn in 2017, the global superdisintegrants market is poised to appreciate to reach an estimated value of USD 576.2 Mn by the end of 2023.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6663   

The pharmaceutical industry is growing at breakneck speed, becoming a significant part of the healthcare sector. This is primarily due to rising populations of both geriatric patients and pediatric patients. Superdisintegrants are helpful for treatment of patients from this demographic as these tablets are easier to swallow. The growth of these demographics is expected to drive market growth. Moreover, generic drugs are in high demand as patents have begun to run out on several popular drug brands, thus opening up the pharmaceutical industry for increased entry of competition and a rise in the manufacturing of generic drugs, thus driving demand for superdisintegrants.

Emerging markets represent significant opportunity as the healthcare sectors in these regions are growing at a swift pace. Moreover, large patient pools are in these countries are expected to increase demand for fast-acting medication. Market players are likely to establish themselves in the region in an effort to leverage the opportunities available in emerging economies.
Players Covered

Prominent market participants that have been profiled in the report include Asahi Kasei Corporation, DFE Pharma, JRS Pharma, Corel Pharma Chem, Ashland Global Holdings Inc., BASF SE, Roquette Freres, DowDuPont Inc., Merck KGaA, and Avantor Performance Materials, LLC

Market Segmentation

MRFR's analysis of the various segments in the market has been performed on the basis of type, formulation, therapeutic area, and region. Types of superdisintegrants have been segmented into synthetic superdisintegrants, natural disintegrants, and others. Among these, the synthetic superdisintegrants segment has been widely used, making it the most significant market segment. However, the natural superdisintegrants segment is growing at a truly rapid pace due to the growing demand for natural ingredients.

Formulations which include superdisintegrants have been segmented into tablets and capsules. Tablets govern a majority share of the total market, while the capsules segment is expected to grow at the highest CAGR during the review period.

Therapeutic areas where superdisintegrants are used have been segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, inflammatory diseases, hematological diseases, and cardiovascular diseases. Among these segments, the gastrointestinal diseases segment is at the forefront of market growth due to the demand for fast acting medicine for these types of diseases. Meanwhile, the oncology segment is growing rapidly and is expected to display the highest CAGR over the forecast period.

Regional Analysis

Led by the U.S, the Americas have captured the largest share of the global superdisintegrants market. The presence of a developed healthcare sector as well as several important market players that have and continue to influence growth and contribute to the sizeable share that this regional market possesses. The region also has a high demand for drugs for many chronic diseases where superdisintegrants are required due to the prevalence of such diseases.

The Asia Pacific superdisintegrants market is likely to grow at the highest pace due to the concentration of rapidly emerging markets in the region. China, Japan, India, and several other country-level markets have a high demand for drugs for chronic diseases. The APAC regional market has several avenues for growth that are expected to open up in the coming years. The regions rapidly growing healthcare sector and the presence of a number of contract manufacturing organizations for pharmaceuticals is likely to have a positive impact on the market.
Top of Form
Bottom of Form
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/superdisintegrants-market-6663
      
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Overactive Bladder Treatment Market to show steady growth, 2019

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cord Blood Banking Services Market Growth and Restrain Factors Analysis By 2023

Market Scenario:
The global cord blood banking services market is expected to exhibit a robust 11.4% CAGR over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global cord blood baking services market is likely to be driven by the growing research into the medical utility of stem cells and cord blood, and the growing establishment of the infrastructure required to create a strong cord blood banking services network.
The umbilical cord blood is a rich source of stem cells and can treat more than 80 genetic diseases. The stem cells also can treat long-lasting diseases such as diabetes, cancer, immune diseases, and blood diseases. Even though a small amount of cord blood can be collected from a single umbilical cord, it comprises a large number of stem cells which can be cultivated and stored for the future use. These cells are collected from hospitals and nursing homes after delivery and stored in cord blood banks (average of 20–25 years) for future use.
Currently, the companies are trying to intensify the awareness about the benefits of cord blood storage. For instance, in 2014, the Institute for Transfusion Medicine and Cord Blood Registry pooled their resources to launch a multi-year initiative for increasing the awareness of cord blood cells.
Factors such as increasing application of cord blood in the treatment of chronic conditions, increasing the focus of federal agencies to set up public banking units, growing awareness regarding this treatment line, and increasing number of facilities across the region are driving the market growth. However, the high cost and probability of non-usage, along with the recommendation driven market by gynecologists are factors hampering the growth of the market.
Key Players
Some of the key players in the global cord blood banking services market are China Cord Blood Corporation (China), Cord Blood America, Inc. (U.S.), CBR Systems, Inc. (U.S.), Cordlife Group Limited (Singapore), Cryo-Cell International, Inc. (U.S.), Cryo-Save AG (Netherland), ViaCord, Inc. (U.S.), Virgin Health Bank (Qatar), California Cryobank Stem Cell Services LLC (U.S.), StemCyte, Inc. (India), Norton Healthcare, Inc. (U.S.), Lifeforce Cryobank Sciences Inc. (U.S.), CordVida (Brazil), CryoHoldco de Latinoamerica, S.A.P.I. De C.V. (Mexico), Vita 34 International (Germany), Maze Cord Blood Laboratories (U.S.), The University of Colorado Cord Blood Bank (U.S.), CorCell (U.S.), Lifebank USA (U.S.), Cryoviva Biotech Pvt. Ltd (India), Genecord (U.S.), AlphaCord (U.S.), FamilyCord (U.S.), Cells4Life (UK), Michigan Blood (U.S.), CariCord (U.S.), LifeCell International Pvt. Ltd (India), Stem Cell Cryobank Inc. (U.S.), Viacord Processing Laboratory (VPL) (U.S.), New Jersey Cord Blood Bank (U.S.), Carter BloodCare (U.S.), Americord Registry (U.S.), and others.
Segmentation
The global cord blood banking services market has been segmented on the basis of storage service, component, application, and end-user.
On the basis of storage service, the global cord blood banking services market can be segmented into public cord blood banks, private cord blood banks, and hybrid cord blood banks.
On the basis of application, the global cord blood banking services market can be segmented into cancers, blood disorders, metabolic disorders, immune disorders, and osteoporosis.
On the basis of component, the global cord blood banking services market can be segmented into cord blood, cord tissue, placenta, and others.
On the basis of end-user, the global cord blood banking services market is segmented into hospitals (medical applications), pharmaceutical research (drug discovery), research institutes (scientific research), and others.
Regional Analysis                     
The global cord blood banking services market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global cord blood banking services market owing to the growing number of service providers, increasing awareness about the long-term benefits of cord blood storage, growing investments in public banking, and reduction in the cost involved in storage. Moreover, the U.S. contributes to a significant market share for the global cord blood banking industry. Factors such growing per capita income, increasing number of storage service providers, and high adoption rate for advanced technologies attributed to the largest market share.
The European cord blood banking services market is the second largest market followed by the Asia Pacific region. The Asia Pacific region is expected to dominate the global cord blood banking services market in terms of growth rate during the forecast period. Though the region presently grasps a minimal share in the global market; it is anticipated to exhibit an enormous growth potential owing to the increasing awareness of stem cell banking and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China. Besides, Asia Pacific is a relatively untapped regional market in comparison with developed regions, which is also a reason why it grants better opportunities for the growth of companies.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cord-blood-banking-services-market-5817
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Chordoma Disease Market - Granular Market Report and Review, 2019

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com